|
1. Biologie
|
|
|
|
Using Darwin’s notebook to outsmart resistance [Cancer World]
|
|
|
|
|
|
The
new wave of interest in Darwinian principles has been spearheaded by
Charles Swanton, Chair in Personalised Cancer Medicine at University
College London’s Cancer Institute, and leader of the research group at
the Francis Crick Institute examining genetic diversity in cancer.
|
|
|
|
|
|
|
1.1 Biologie - Gènes
|
|
|
|
|
3.1 Tabac
|
|
|
|
3.8 Prévention - Alimentation
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
4.9 Dép., diag. & prono. - Sein
|
|
|
|
5. Traitements
|
|
|
Richard Lehman’s journal review—13 March 2017 [BMJ]
|
|
|
|
|
|
Gefinitib,
erlotinib, sunitinib, cabozantinib: they may think they’re his nibs,
but they are not helping the majority of people with cancer. “Inib,” you
may have guessed, really stands for “inhibitor.” It also stands for the
Institute of Northern Ireland Beekeepers. Perhaps a good summary of the
tyrosine kinase inhibitors would be “More Buzz than Honey.”
|
|
|
|
|
|
|
|
5.12 Immunothérapies
|
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
Possible Cures. Mystery Deaths. Daunting Costs. Can CAR-T Be Tamed? [Xconomy]
|
|
|
|
|
|
Now
the field’s first-ever regulatory approval is looking like a strong
possibility, making this a watershed year for CAR-T therapy. But the
supercharged T cells remain an enigma. Experts are wrestling with the
super-hero problem that threatens to limit their usefulness: How can the
cells be engineered to kill cancer without running amok?
|
|
|
|
|
|
|
5.12.3 Immunothérapies-combinaisons
|
|
|
|
5.2 Pharma
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
|
|
|
|
|
6.10 Politiques
|
|
|
|
6.6 Publications
|
|
|